Imjudo Drug Information

Generic name: TREMELIMUMAB

CTLA-4-directed Blocking Antibody [EPC]

Save on Imjudo at your pharmacy Compare prices near you and start saving today—no enrollment required.

Uses of Imjudo

Hepatocellular Carcinoma IMJUDO, in combination with durvalumab, is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC).

Non-Small Cell Lung Cancer (NSCLC) IMJUDO, in combination with durvalumab and platinum-based chemotherapy, is indicated for the treatment of adult patients with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.

Dosage & Administration of Imjudo

Preparation and Administration Preparation •

Visually inspect drug product for particulate matter and discoloration. Discard if the solution is cloudy, discolored, or visible particles are observed. • Do not shake the vial. • Withdraw the required volume from the vial(s) of IMJUDO and discard the vial with any unused portion. • Transfer into an intravenous bag containing 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP and dilute to a concentration between 0.1 mg/mL and 10 mg/mL. Mix diluted solution by gentle inversion.

Do not shake the solution. Storage of Diluted IMJUDO Infusion Solution • IMJUDO does not contain a preservative. Administer infusion solution immediately once prepared.

If infusion solution is not administered immediately and needs to be stored, the total time from preparation to the start of administration should not exceed: 24 hours in a refrigerator at 2°C to 8°C (36°F to 46°F) 24 hours at room temperature up to 30°C (86°F) • Do not freeze. • Do not shake. Administration • Administer IMJUDO infusion solution intravenously over 60 minutes through an intravenous line containing a sterile, low-protein binding 0.2 or 0.22 micron filter. • Use separate infusion bags and filters for each drug product. IMJUDO In Combination with Other Products • Administer all drug products as separate intravenous infusions. • Do not co-administer other drugs through the same infusion line. • For platinum-based chemotherapy, refer to Prescribing Information for administration information. • For pemetrexed treatment, refer to Prescribing Information for administration information.

Combination Regimens: Order of Infusions IMJUDO in Combination with Durvalumab • Infuse IMJUDO, followed by durvalumab on the same day of dosing. IMJUDO in Combination with Durvalumab and Platinum-based Chemotherapy • Infuse IMJUDO first, followed by durvalumab and then platinum-based chemotherapy on the day of dosing. IMJUDO in Combination with Durvalumab and Pemetrexed Therapy • Infuse IMJUDO first, followed by durvalumab and then pemetrexed treatment on the day of dosing.

Combination Regimens: Infusion Instructions IMJUDO in Combination with Durvalumab • Observe patient for 60 minutes following completion of IMJUDO infusion. Then administer durvalumab as a separate intravenous infusion over 60 minutes IMJUDO in Combination with Durvalumab and Platinum-based Chemotherapy/ Pemetrexed Therapy Cycle 1: • Infuse IMJUDO over one hour. One to two hours after completion of IMJUDO infusion, infuse durvalumab over one hour.

One to two hours after completion of durvalumab infusion, administer platinum-based chemotherapy. Subsequent Cycles: If there are no infusion reactions during cycle 1, subsequent cycles of durvalumab can be given immediately after IMJUDO. The time between the end of the durvalumab infusion and the start of chemotherapy can be reduced to 30 minutes.

Table 1. Recommended dosage of IMJUDO
Indication	Recommended IMJUDO Dosage	Duration of Therapy
uHCC	Patients with a body weight of 30 kg and more: • A single dose of IMJUDO Administer IMJUDO prior to durvalumab on the same day. 300 mg followed by durvalumab Refer to the Prescribing Information for durvalumab dosing information. 1,500 mg at Day 1 of Cycle 1; • Continue durvalumab 1,500 mg as a single agent every 4 weeks Patients with a body weight of less than 30 kg: • A single dose of IMJUDO 4 mg/kg followed by durvalumab 20 mg/kg at Day 1 of Cycle 1; • Continue durvalumab 20 mg/kg as a single agent every 4 weeks	After Cycle 1 of combination therapy, administer durvalumab as a single agent every 4 weeks until disease progression or unacceptable toxicity

Table 3: Recommended Regimen and Dosage
Tumor Histology	Patient Weight	IMJUDO Dosage	Durvalumab Refer to the Prescribing Information for dosing information. Dosage	Platinum-based Chemotherapy Regimen
Non-Squamous	≥ 30 kg	75 mg	1,500 mg	• carboplatin & nab-paclitaxel OR • carboplatin or cisplatin & pemetrexed
Non-Squamous	< 30 kg	1 mg/kg	20 mg/kg
Squamous	≥ 30 kg	75 mg	1,500 mg	• carboplatin & nab-paclitaxel OR • carboplatin or cisplatin & gemcitabine
Squamous	< 30 kg	1 mg/kg	20 mg/kg

Table 4. Recommended Dosage Modifications for Adverse Reactions
Adverse Reaction	Severity Based on National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03.	Dosage Modification
Immune-Mediated Adverse Reactions [see Warnings and Precautions (5.1) ]
Pneumonitis	Grade 2	Withhold Resume in patients with complete or partial resolution (Grade 0 to 1) after corticosteroid taper. Permanently discontinue if no complete or partial resolution within 12 weeks of initiating steroids or an inability to reduce corticosteroid dose to 10 mg of prednisone or less per day (or equivalent) within 12 weeks of initiating corticosteroids.
Pneumonitis	Grade 3 or 4	Permanently discontinue
Colitis	Grade 2	Withhold
Colitis	Grade 3 or 4	Permanently discontinue
Intestinal perforation	Any grade	Permanently discontinue
Hepatitis with no tumor involvement of the liver	ALT or AST increases to more than 3 and up to 8 times the ULN or total bilirubin increases to more than 1.5 and up to 3 times ULN	Withhold
Hepatitis with no tumor involvement of the liver	ALT or AST increases to more than 8 times ULN or total bilirubin increases to more than 3 times the ULN	Permanently discontinue
Hepatitis with tumor involvement of the liver If AST and ALT are less than or equal to ULN at baseline in patients with liver involvement, withhold or permanently discontinue durvalumab based on recommendations for hepatitis with no liver involvement.	AST or ALT is more than 1 and up to 3 times ULN at baseline and increases to more than 5 and up to 10 times ULN or AST or ALT is more than 3 and up to 5 times ULN at baseline and increases to more than 8 and up to 10 times ULN	Withhold
	AST or ALT increases to more than 10 times ULN or Total bilirubin increases to more than 3 times ULN	Permanently discontinue
Endocrinopathies	Grade 3 or 4	Withhold until clinically stable or permanently discontinue depending on severity
Nephritis with Renal Dysfunction	Grade 2 or 3 increased blood creatinine	Withhold
Nephritis with Renal Dysfunction	Grade 4 increased blood creatinine	Permanently discontinue
Exfoliative Dermatologic Conditions	Suspected SJS, TEN, or DRESS	Withhold
Exfoliative Dermatologic Conditions	Confirmed SJS, TEN, or DRESS	Permanently discontinue
Myocarditis	Grade 2, 3, or 4	Permanently discontinue
Neurological Toxicities	Grade 2	Withhold
Neurological Toxicities	Grade 3 or 4	Permanently discontinue
Other Adverse Reactions
Infusion-related reactions [see Warnings and Precautions (5.2) ]	Grade 1 or 2	Interrupt or slow the rate of infusion
	Grade 3 or 4	Permanently discontinue
ALT = alanine aminotransferase, AST = aspartate aminotransferase, DRESS = Drug Rash with Eosinophilia and Systemic Symptoms, SJS = Stevens Johnson Syndrome, TEN = toxic epidermal necrolysis, ULN = upper limit normal

Side Effects of Imjudo

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data described in the Warnings and Precautions reflect exposure to IMJUDO 300 mg in combination with durvalumab 1,500 mg in 388 patients in HIMALAYA. In the HIMALAYA study patients received IMJUDO 300 mg administered as a single intravenous infusion in combination with durvalumab 1,500 mg on the same day, followed by durvalumab every 4 weeks.

In this pooled safety population, the most common Grade 3 or 4 (> 10%) laboratory abnormalities were neutropenia ( %). The data described in this section reflect exposure to IMJUDO in patients with uHCC included in the HIMALAYA study and in patients with metastatic NSCLC enrolled in the POSEIDON study. Hepatocellular Carcinoma Unresectable HCC - HIMALAYA The safety of IMJUDO administered in combination with durvalumab was evaluated in a total of 388 patients with uHCC in HIMALAYA, a randomized, open-label, multicenter study.

Serious adverse reactions occurred in 41% of patients who received IMJUDO in combination with durvalumab. The most common adverse reactions (occurring in ≥ 20% of patients) were rash, diarrhea, fatigue, pruritus, musculoskeletal pain, and abdominal pain. Dosage interruptions or delay of the treatment regimen due to an adverse reaction occurred in 35% of patients.

Table 5 summarizes the adverse reactions that occurred in patients treated with IMJUDO in combination with durvalumab in the HIMALAYA study. Table 5. Table 6 summarizes the laboratory abnormalities that occurred in patients treated with IMJUDO in combination with durvalumab in the HIMALAYA study.

Table 6. Laboratory Abnormalities Worsening from Baseline Occurring in ≥ Non-Small Cell Lung Cancer Metastatic NSCLC – POSEIDON The safety of IMJUDO in combination with durvalumab and platinum-based chemotherapy in patients with metastatic NSCLC was evaluated in POSEIDON (NCT03164616), a randomized, open-label, multicenter, active-controlled trial. Treatment was continued with durvalumab as a single agent (or with durvalumab and histology-based pemetrexed for non-squamous patients, based on the investigator’s decision) until disease progression or unacceptable toxicity.

The trial excluded patients with active or prior autoimmune disease or with medical conditions that required systemic corticosteroids or immunosuppressants. Serious adverse reactions occurred in 44% of patients receiving IMJUDO in combination with durvalumab and platinum-based chemotherapy. Fatal adverse reactions occurred in a total of 4.2% of patients receiving IMJUDO in combination with durvalumab and platinum-based chemotherapy.

Permanent discontinuation of IMJUDO or durvalumab due to an adverse reaction occurred in 17% of the patients. Adverse reactions which resulted in permanent discontinuation of IMJUDO or durvalumab in > 2% of patients included pneumonia. Dosage interruptions or delay of IMJUDO and durvalumab due to an adverse reaction occurred in 41% of patients.

Adverse reactions which required dosage interruption or delay of IMJUDO and durvalumab in > 1% of patients included anemia, leukopenia/white blood cell count decreased, pneumonia, pneumonitis, colitis, diarrhea, hepatitis, rash, asthenia, amylase increased, alanine aminotransferase increased, aspartate aminotransferase increased, lipase increased, neutropenia/neutrophil count decreased, and thrombocytopenia/platelet count decreased. The most common adverse reactions (occurring in ≥ 20% of patients) were nausea, fatigue, musculoskeletal pain, decreased appetite, rash, and diarrhea. Grade 3 or 4 laboratory abnormalities (≥ 10%) were neutropenia, anemia, leukopenia, lymphocytopenia, lipase increased, hyponatremia and thrombocytopenia.

Table 7 summarizes the adverse reactions in POSEIDON. Table 7. Adverse Reactions (≥ 10%) in Patients with NSCLC Who Received IMJUDO in the POSEIDON Study Table 8 summarizes the laboratory abnormalities in POSEIDON.

Table 8: Select Laboratory Abnormalities (≥ 10%) That Worsened from Baseline in Patients with NSCLC Who Received IMJUDO in the POSEIDON Study

Table 5. Adverse Reactions Occurring in ≥ 10% Patients in the HIMALAYA study
	IMJUDO and Durvalumab (N=388)		Sorafenib (N=374)
Adverse Reaction	All Grades (%)	Grade 3-4 (%)	All Grades (%)	Grade 3-4 (%)
Gastrointestinal disorders
Diarrhea Represents a composite of multiple related terms.	27	6	45	4.3
Abdominal pain	20	1.8	24	4
Nausea	12	0	14	0
Skin and subcutaneous tissue disorders
Rash	32	2.8	57	12
Pruritus	23	0	6	0.3
Metabolism and nutrition disorders
Decreased appetite	17	1.3	18	0.8
General disorders and administration site conditions
Fatigue	26	3.9	30	6
Pyrexia	13	0.3	9	0.3
Psychiatric disorders
Insomnia	10	0.3	4.3	0
Endocrine disorders
Hypothyroidism	14	0	6	0
Musculoskeletal and Connective Tissue Disorders
Musculoskeletal pain	22	2.6	17	0.8

Table 6. Laboratory Abnormalities Worsening from Baseline Occurring in ≥ 20% of Patients in the HIMALAYA study
	IMJUDO and Durvalumab		Sorafenib
Laboratory Abnormality	Any grade Graded according to NCI CTCAE version 4.03. (%) Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: IMJUDO with durvalumab (range: 367-378) and sorafenib (range: 344-352).	Grade 3 or 4 (%)	Any grade (%)	Grade 3 or 4 (%)
Chemistry
Aspartate Aminotransferase increased	63	27	55	21
Alanine Aminotransferase increased	56	18	53	12
Sodium decreased	46	15	40	11
Bilirubin increased	41	8	47	11
Alkaline Phosphatase increased	41	8	44	5
Glucose increased	39	14	29	4
Calcium decreased	34	0	43	0.3
Albumin decreased	31	0.5	37	1.7
Potassium increased	28	3.8	21	2.6
Creatinine increased	21	1.3	15	0.9
Hematology
Hemoglobin decreased	52	4.8	40	6
Lymphocytes decreased	41	11	39	10
Platelets decreased	29	1.6	35	3.1
Leukocytes decreased	20	0.8	30	1.1

Table 7. Adverse Reactions (≥ 10%) in Patients with NSCLC Who Received IMJUDO in the POSEIDON Study
	IMJUDO with durvalumab and platinum-based chemotherapy N = 330		Platinum-based chemotherapy N = 333
Adverse Reaction	All Grades (%)	Grade 3 or 4 (%)	All Grades (%)	Grade 3 or 4 (%)
Respiratory, thoracic and mediastinal disorders
Cough/Productive Cough Includes cough and productive cough.	12	0	8	0.3
Gastrointestinal disorders
Nausea	42	1.8	37	2.1
Diarrhea	22	1.5	15	1.5
Constipation	19	0	24	0.6
Vomiting	18	1.2	14	1.5
Stomatitis Includes mucosal inflammation and stomatitis.	10	0	6	0.3
Endocrine disorders
Hypothyroidism Includes blood thyroid stimulating hormone increased and hypothyroidism.	13	0	2.1	0
Skin and subcutaneous tissue disorders
Rash Includes eczema, erythema, dermatitis, drug eruption, erythema multiforme, pemphigoid, rash, rash maculo-papular, rash papular, rash pruritic and rash pustular.	27	2.4	10	0.6
Alopecia	10	0	6	0
Pruritus	11	0	4.5	0
General disorders and administration site conditions
Fatigue/Asthenia Includes asthenia and fatigue.	36	5	32	4.5
Pyrexia Includes body temperature increased, hyperpyrexia, hyperthermia, and pyrexia.	19	0	8	0
Edema Includes face edema, localized edema, and edema peripheral.	10	0	10	0.6
Musculoskeletal and connective tissue disorders
Musculoskeletal Pain Includes arthralgia, arthritis, back pain, bone pain, musculoskeletal chest pain, musculoskeletal pain, myalgia, neck pain, non-cardiac chest pain, spinal pain.	29	0.6	22	1.5
Metabolism and nutrition disorders
Decreased appetite	28	1.5	25	1.2
Infections and Infestations
Pneumonia Includes lower respiratory tract infection, pneumocystis jirovecii pneumonia, pneumonia, pneumonia aspiration, pneumonia bacterial.	17	8	12	4.2
Upper respiratory tract infections Includes laryngitis, nasopharyngitis, pharyngitis, rhinitis, sinusitis, tonsillitis, tracheobronchitis and upper respiratory tract infection.	15	0.6	9	0.9
Nervous system disorders
Headache Includes headache, migraine.	11	0	8	0.6

Table 8: Select Laboratory Abnormalities (≥ 10%) That Worsened from Baseline in Patients with NSCLC Who Received IMJUDO in the POSEIDON Study
Laboratory Abnormality	IMJUDO with Durvalumab and Platinum-based chemotherapy		Platinum-based chemotherapy
Laboratory Abnormality	All Grades (%)	Grade 3 or 4 (%)	All Grades (%)	Grade 3 or 4 (%)
Chemistry
Lipase increased	35	14	25	5
Hyponatremia	55	13	50	11
Hypernatremia	15	0	14	0
Amylase increased	41	9	25	6
Hypokalemia	21	7	17	2.8
Hyperglycemia	42	6	37	3.1
Increased ALT	64	6	56	4.7
Increased AST	63	5	55	2.2
Blood creatinine increased	89	4.0	83	1.9
Increased Alkaline Phosphatase	33	3.4	26	1.2
Gamma Glutamyl Transferase increased	38	2.2	35	4.7
Hyperkalemia	49	2.2	35	2.8
Albumin decreased	27	1.9	18	0.9
Hypocalcemia	58	0.9	49	0.9
Hypomagnesemia	12	4	23	0
Bilirubinemia	16	0.9	8	0.3
Hematology
Neutropenia	71	37	69	32
Anemia	84	24	84	25
Leukopenia	77	21	81	18
Lymphocytopenia	67	20	60	19
Thrombocytopenia	53	11	54	12

Warnings & Cautions for Imjudo

Severe and Fatal Immune-Mediated Adverse Reactions IMJUDO is a monoclonal antibody that blocks T-cell inhibitory signals induced by the CTLA-4 pathway, thereby removing inhibition of the immune response. In combination with durvalumab, a PD-L1 inhibitor, these drugs have the potential for induction of immune-mediated adverse reactions. Immune-mediated adverse reactions listed herein may not be inclusive of all possible severe and fatal immune-mediated reactions.

Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue. Immune-mediated adverse reactions can occur at any time after starting IMJUDO in combination with durvalumab. While immune-mediated adverse reactions usually manifest during treatment, immune-mediated adverse reactions can also manifest after discontinuation of IMJUDO and/or durvalumab.

Early identification and management of immune-mediated adverse reactions are essential to ensure safe use of IMJUDO in combination with durvalumab. Monitor for signs and symptoms that may be clinical manifestations of underlying immune-mediated adverse reactions. Evaluate clinical chemistries including liver enzymes, creatinine, adrenocorticotropic hormone (ACTH) level, and thyroid function at baseline and before each dose.

Institute medical management promptly, including specialty consultation as appropriate. Withhold or permanently discontinue IMJUDO and durvalumab depending on severity. In general, if combination of IMJUDO and durvalumab requires interruption or discontinuation, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less.

Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with corticosteroid therapy. Toxicity management guidelines for adverse reactions that do not necessarily require systemic steroids (e.g., endocrinopathies and dermatologic reactions) are discussed below.

Immune-Mediated Pneumonitis IMJUDO in combination with durvalumab can cause immune-mediated pneumonitis, which may be fatal. Events resolved in 3 of the 5 patients and resulted in permanent discontinuation in 1 patient. Systemic corticosteroids were required in all patients; of these, 4 patients required high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day).

One patient (1/5) required other immunosuppressants. Events resolved in 11 of the 21 patients and resulted in permanent discontinuation in 7 patients. Systemic corticosteroids were required in all patients with immune-mediated pneumonitis, while 1 patient (1/21) required other immunosuppressants.

IMJUDO in combination with durvalumab can cause immune-mediated colitis that is frequently associated with diarrhea. Cytomegalovirus (CMV) infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis. In cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies.

Events resolved in 22 of the 23 patients and resulted in permanent discontinuation in 5 patients. All patients received systemic corticosteroids, and 20 of the 23 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Three patients also received other immunosuppressants.

Intestinal perforation has been observed in other studies of IMJUDO in combination with durvalumab. Events resolved in 33 of the 39 patients and resulted in permanent discontinuation in 11 patients. Systemic corticosteroids were required in all patients with immune-mediated colitis, while 4 patients (4/39) required other immunosuppressants.

Intestinal perforation and large intestine perforation were reported in 0.1% of patients receiving IMJUDO in combination with durvalumab. Events resolved in 12 of the 29 patients and resulted in permanent discontinuation in 9 patients. Eight patients (8/29) required other immunosuppressants.

Events resolved in 12 of the 23 patients and resulted in permanent discontinuation in 27 patients. Systemic corticosteroids were required in all patients with immune-mediated hepatitis, while 2 patients (2/23) required use of other immunosuppressants. Immune-Mediated Endocrinopathies Adrenal Insufficiency: IMJUDO in combination with durvalumab can cause primary or secondary adrenal insufficiency.

For Grade 2 or higher adrenal insufficiency, initiate symptomatic treatment, including hormone replacement as clinically indicated. Withhold or permanently discontinue IMJUDO in combination with durvalumab based on the severity. Events resolved in 2 of the 6 patients.

Events resolved in 2 of the 13 patients and resulted in permanent discontinuation in 1 patient. Systemic corticosteroids were required in all patients with adrenal insufficiency. One patient also required endocrine therapy.

Hypophysitis can present with acute symptoms associated with mass effect such as headache, photophobia, or visual field cuts. Hypophysitis can cause hypopituitarism. IMJUDO with Durvalumab Immune-mediated hypophysitis/hypopituitarism occurred in 1% (4/388) of patients receiving IMJUDO in combination with durvalumab.

Events resolved in 2 of the 4 patients. Two patients also required endocrine therapy. Events resulted in permanent discontinuation in 1 patient.

Four patients also required endocrine therapy. Thyroid Disorders: IMJUDO in combination with durvalumab can cause immune-mediated thyroid disorders. Thyroiditis can present with or without endocrinopathy.

Hypothyroidism can follow hyperthyroidism. Initiate hormone replacement therapy for hypothyroidism or institute medical management of hyperthyroidism as clinically indicated. Thyroiditis: IMJUDO with Durvalumab Immune-mediated thyroiditis occurred in 1.5% (6/388) of patients receiving IMJUDO in combination with durvalumab.

All patients required other therapy including hormone replacement therapy, thiamazole, carbimazole, propylthiouracil, perchlorate, calcium channel blocker, or beta-blocker. IMJUDO with Durvalumab and Platinum-Based Chemotherapy Immune-mediated thyroiditis occurred in 1.2% (7/596) of patients receiving IMJUDO in combination with durvalumab and platinum-based chemotherapy. Events resolved in 2 of the 7 patients and one resulted in permanent discontinuation.

Systemic corticosteroids were required in 2 patients (2/7) with immune-mediated thyroiditis, while all patients required endocrine therapy. Events resolved in 15 of the 18 patients. Two patients (2/18) required high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day).

Events resolved in 21 of the 30 patients. Hypothyroidism: IMJUDO with Durvalumab Immune-mediated hypothyroidism occurred in 11% (42/388) of patients receiving IMJUDO in combination with durvalumab. Events resolved in 5 of the 42 patients.

One patient received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Systemic corticosteroids were required in 2 patients (2/51) and all patients required endocrine therapy. Type 1 Diabetes Mellitus, Which Can Present with Diabetic Ketoacidosis: Monitor patients for hyperglycemia or other signs and symptoms of diabetes.

Initiate treatment with insulin as clinically indicated. IMJUDO with Durvalumab Two patients (0.5%, 2/388) had events of hyperglycemia requiring insulin therapy that had not resolved at last follow-up. All patients required endocrine therapy.

Immune-Mediated Nephritis with Renal Dysfunction IMJUDO in combination with durvalumab can cause immune-mediated nephritis. Immune-Mediated Dermatology Reactions IMJUDO in combination with durvalumab can cause immune-mediated rash or dermatitis. Exfoliative dermatitis, including Stevens Johnson Syndrome (SJS), drug rash with eosinophilia and systemic symptoms (DRESS), and toxic epidermal necrolysis (TEN), has occurred with CTLA-4 and PD-1/L-1 blocking antibodies.

Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate non-exfoliative rashes. One patient received other immunosuppressants. Events resolved in 32 of the 43 patients and resulted in permanent discontinuation in 2 patients.

Systemic corticosteroids were required in all patients with immune-mediated rash or dermatitis. Events resolved in 6 of the 9 patients. Other Immune-Mediated Adverse Reactions The following clinically significant, immune-mediated adverse reactions occurred at an incidence of less than 1% each in patients who received IMJUDO in combination with durvalumab or were reported with the use of other immune-checkpoint inhibitors.

Cardiac/vascular: Myocarditis, pericarditis, vasculitis. Nervous system: Meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis (including exacerbation), Guillain-Barré syndrome, nerve paresis, autoimmune neuropathy. Ocular: Uveitis, iritis, and other ocular inflammatory toxicities can occur.

Some cases can be associated with retinal detachment. Various grades of visual impairment to include blindness can occur. If uveitis occurs in combination with other immune-mediated adverse reactions, consider a Vogt-Koyanagi-Harada-like syndrome, as this may require treatment with systemic steroids to reduce the risk of permanent vision loss.

Gastrointestinal: Gastritis, duodenitis. Musculoskeletal and connective tissue disorders: Myositis/polymyositis, rhabdomyolysis and associated sequelae including renal failure, arthritis, polymyalgia rheumatica. Endocrine: Hypoparathyroidism.

Hematologic/Immune: Hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, and immune thrombocytopenia. Other: Myocarditis-Myositis-Myasthenia Gravis (or Myasthenia-Like) Overlap Syndrome, reported as the co-occurrence of either two or all three adverse reactions.

Infusion-Related Reactions IMJUDO in combination with durvalumab can cause severe or life-threatening infusion-related reactions. Monitor for signs and symptoms of infusion-related reactions. Interrupt, slow the rate of, or permanently discontinue IMJUDO and durvalumab based on the severity.

For Grade 1 or 2 infusion-related reactions, consider using pre-medications with subsequent doses. IMJUDO with Durvalumab Infusion-related reactions occurred in 10 (2.6%) patients receiving IMJUDO in combination with durvalumab. IMJUDO with Durvalumab and Platinum-Based Chemotherapy Infusion-related reactions occurred in 2.9% (17/596) of patients receiving IMJUDO in combination with durvalumab and platinum-based chemotherapy, including Grade 3 (0.3%) adverse reactions.

Embryo-Fetal Toxicity Based on findings from animal studies and its mechanism of action, IMJUDO can cause fetal harm when administered to a pregnant woman. In animal studies, CTLA-4 blockade is associated with higher incidence of pregnancy loss. Advise pregnant women and females of reproductive potential of the potential risk to a fetus.

Advise females of reproductive potential to use effective contraception during treatment with IMJUDO and for 3 months after the last dose of IMJUDO.

Pregnancy Safety for Imjudo

Pregnancy Risk summary Based on findings from animal studies and its mechanism of action, IMJUDO can cause fetal harm when administered to a pregnant woman. There are no available data on the use of IMJUDO in pregnant women. In animal studies, CTLA-4 blockade is associated with increased risk of immune-mediated rejection of the developing fetus and fetal death ( see Data ).

Human immunoglobulin G2 (IgG2) is known to cross the placental barrier; therefore, IMJUDO has the potential to be transmitted from the mother to the developing fetus. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is respectively.

Data Animal Data In a reproduction study, administration of tremelimumab-actl to pregnant cynomolgus monkeys during the period of organogenesis was not associated with maternal toxicity or effects on embryo-fetal development at exposure levels approximately 4 to 31-times higher than those observed at a recommended dose range of 75 mg to 300 mg based on area under the curve (AUC). CTLA-4 plays a role in maintaining maternal immune tolerance to the fetus to preserve pregnancy and in immune regulation of the newborn. In a murine model of pregnancy, CTLA-4 blockade resulted in increased resorptions and reduced live fetuses.

Mated genetically engineered mice heterozygous for CTLA-4 (CTLA-4+/-) gave birth to CTLA-4+/- offspring and offspring deficient in CTLA-4 (homozygous negative, CTLA-4-/-) that appeared healthy at birth. The CTLA-4-/- homozygous negative offspring developed signs of a lymphoproliferative disorder and died by 3 to 4 weeks of age with multiorgan tissue destruction. Based on its mechanism of action, fetal exposure to tremelimumab-actl may increase the risk of developing immune-mediated disorders or altering the normal immune response.

Pediatric Use of Imjudo

Pediatric Use The safety and effectiveness of IMJUDO have not been established in pediatric patients. Safety and efficacy were assessed but not established in a multi-center, open-label study (NCT03837899) in which 41 pediatric patients aged 1 to < 17 years with advanced solid tumors received IMJUDO in combination with durvalumab. No new safety signals were observed in pediatric patients in this study.

Tremelimumab-actl systemic exposure in pediatric patients ≥ 35 kg was within the range of the values previously observed in adults given the same weight-based dose, whereas the systemic exposure in pediatric patients < 35 kg was lower than that of adults.

Clinical Studies of Imjudo

Hepatocellular Carcinoma (HCC) Unresectable HCC - HIMALAYA

The efficacy of IMJUDO in combination with durvalumab was evaluated in the HIMALAYA study (NCT03298451), a randomized (1:1:1), open-label, multicenter study in patients with confirmed uHCC who had not received prior systemic treatment for HCC. Patients were randomized to one of two investigational arms (IMJUDO plus durvalumab or durvalumab) or sorafenib. The efficacy assessment of IMJUDO is based on patients randomized to the IMJUDO plus durvalumab arm versus the sorafenib arm.

Randomization was stratified by macrovascular invasion (MVI) (yes or no), etiology of liver disease (hepatitis B virus vs. hepatitis C virus vs. others) and ECOG performance status (0 vs. 1). The study enrolled patients with BCLC Stage C or B (not eligible for locoregional therapy). The study excluded patients with co-infection of viral hepatitis B and hepatitis C; active or prior documented gastrointestinal (GI) bleeding within 12 months; ascites requiring non-pharmacologic intervention within 6 months; hepatic encephalopathy within 12 months before the start of treatment; active or prior documented autoimmune or inflammatory disorders.

Esophagogastroduodenoscopy was not mandated prior to enrollment but adequate endoscopic therapy, according to institutional standards, was required for patients with a history of esophageal variceal bleeding or those assessed as high risk for esophageal variceal bleeding by the treating physician. Study treatment was permitted beyond disease progression if the patient was clinically stable and was deriving clinical benefit as determined by the investigator. The major efficacy outcome measure was overall survival (OS) between the IMJUDO plus durvalumab arm versus the sorafenib arm.

Additional efficacy outcomes were investigator-assessed progression-free survival (PFS), objective response rate (ORR) and duration of response (DoR) according to RECIST v1.1. Tumor assessments were conducted every 8 weeks for the first 12 months and then every 12 weeks thereafter. Efficacy results are presented in Table 9 and Figure 1.

Table 9. Efficacy Results for HIMALAYA Study CI=Confidence Interval, HR=Hazard Ratio, NR=Not Reached Figure 1. Kaplan-Meier curve of OS Figure 1

Metastatic NSCLC Metastatic NSCLC – POSEIDON

The efficacy of IMJUDO in combination with durvalumab and platinum-based chemotherapy in previously untreated metastatic NSCLC patients with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations was investigated in POSEIDON, a randomized, multicenter, active-controlled, open-label trial (NCT03164616). Eligible patients had Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 and must have had no prior chemotherapy or any other systemic therapy for metastatic NSCLC. Choice of platinum-based chemotherapy was at the Investigator’s discretion, taking into consideration the calculated creatinine clearance.

Patients with active and/or untreated brain metastases; a history of active primary immunodeficiency; autoimmune disorders including active or prior documented autoimmune or inflammatory disorders; use of systemic immunosuppressants within 14 days before the first dose of the treatment except physiological dose of systemic corticosteroids were ineligible. Randomization was stratified by tumor cells (TC) PD-L1 expression (TC ≥ 50% vs. TC < 50%), disease stage Stage IVA vs.

Stage IVB, and histology (non-squamous vs. squamous). Patients were randomized 1:1:1 to receive IMJUDO in combination with durvalumab and platinum-based chemotherapy according to the regimens listed below, durvalumab and platinum-based chemotherapy (an unapproved regimen for metastatic NSCLC), or platinum-based chemotherapy. Patients could receive an additional 2 cycles (a total of 6 cycles post-randomization), as clinically indicated, at Investigator’s discretion.

Durvalumab and histology-based pemetrexed continued every 4 weeks until disease progression or unacceptable toxicity. Patients with disease progression during durvalumab monotherapy were given the option to be retreated with 4 additional cycles of IMJUDO in combination with durvalumab. Tumor assessments were performed at Week 6, Week 12, and then every 8 weeks thereafter.

The major efficacy outcome measures were progression free survival (PFS) and overall survival (OS) of IMJUDO and durvalumab in combination with platinum-based chemotherapy compared to platinum-based chemotherapy alone. Additional efficacy outcome measures were overall response rate (ORR) and duration of response (DoR). PFS, ORR, and DoR were assessed using Blinded Independent Central Review (BICR) according to RECIST v1.1.

A total of 675 patients were randomized to receive either IMJUDO with durvalumab and platinum-based chemotherapy (n=338) or platinum-based chemotherapy (n=337). Efficacy results are summarized in Table 10 and Figure 2. Table 10.

Efficacy Results for P EIDON Figure 2 figure_2_data

Table 9. Efficacy Results for HIMALAYA Study
Endpoint	IMJUDO and Durvalumab (N=393)	Sorafenib (N=389)
OS
Number of deaths (%)	262 (66.7)	293 (75.3)
Median OS (months) (95% CI)	16.4 (14.2, 19.6)	13.8 (12.3, 16.1)
HR (95% CI) HR (IMJUDO and durvalumab vs. sorafenib) based on the stratified Cox proportional hazard model.	0.78 (0.66, 0.92)
p-value Based on a stratified log-rank test. Based on a Lan-DeMets alpha spending function with O'Brien Fleming type boundary and the actual number of events observed, the boundary for declaring statistical significance for IMJUDO and durvalumab vs. sorafenib was 0.0398 (Lan and DeMets 1983).	0.0035
PFS
Number of events (%)	335 (85.2)	327 (84.1)
Median PFS (months) (95% CI)	3.8 (3.7, 5.3)	4.1 (3.7, 5.5)
HR (95% CI)	0.90 (0.77, 1.05)
ORR
ORR % (95% CI) Confirmed complete response or partial response. Based on Clopper-Pearson method.	20.1 (16.3, 24.4)	5.1 (3.2, 7.8)
Complete Response n (%)	12 (3.1)	0
Partial Response n (%)	67 (17.0)	20 (5.1)
DoR
Median DoR (months) (95% CI)	22.3 (13.7, NR)	18.4 (6.5, 26.0)
% with duration ≥ 6 months	82.3	78.9
% with duration ≥ 12 months	65.8	63.2

Table 10. Efficacy Results for POSEIDON
	IMJUDO with durvalumab and platinum-based chemotherapy (n=338)	Platinum-based chemotherapy (n=337)
OS PFS/OS results are based on planned analyses which occurred 25/45 months respectively after study initiation.
Number of deaths (%)	251 (74)	285 (85)
Median OS (months) (95% CI)	14.0 (11.7, 16.1)	11.7 (10.5, 13.1)
HR (95% CI)	0.77 (0.65, 0.92)
p-value 2-sided p-values based on log-rank tests stratified by PD-L1, histology and disease stage and compared to a boundary value of 0.00735 for PFS and 0.00797 for OS.	0.00304
PFS
Number of events (%)	238 (70)	258 (77)
Median PFS (months) (95% CI)	6.2 (5.0, 6.5)	4.8 (4.6, 5.8)
HR (95% CI)	0.72 (0.60, 0.86)
p-value	0.00031
ORR % (95% CI) Confirmed responses with 95% Clopper-Pearson confidence intervals.	39 (34, 44)	24 (20, 29)
Median DoR (months) (95% CI)	9.5 (7.2, NR)	5.1 (4.4, 6.0)
NR=Not Reached, CI=Confidence Interval

Drug information sourced from the FDA. This content is for informational purposes only and does not constitute medical advice. Consult a healthcare professional before making any medication decisions.

Ready to save on Imjudo?

Compare prescription prices at over 70,000 pharmacies and start saving today—no enrollment required.

Compare Imjudo Prices